News & Events

SUNNYVALE, CA / ACCESSWIRE / May 21, 2015 / Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced that Patricia Scheller, CEO and Scott Durbin, CFO will present at the SeeThru Equity 4th Annual Microcap Investor Conference at the Convene Grand Central in Midtown Manhattan, New York, on Thursday, May 28th.

Ms. Scheller and Mr. Durbin will provide an overview of the Company's business and products, details of its commercial efforts and updates on newly signed partnerships at the event. The Company's recorded presentation, including audio, will be available immediately following the meeting at: http://wsw.com/webcast/seethru11/vivmf.

Members of the investment community interested in meeting with management that day can contact their representative at SeeThru Equity, or Amato and Partners.

"We are pleased to be participating in one of the premier annual microcap investor conferences," said Patricia Scheller, Chief Executive Officer, "We look forward to interacting with as many of the over 600 attendees as possible during the meeting, and sharing the Viveve story with them."

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve(R) System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

Contact:

 

Amato and Partners, LLC

Investor Relations Counsel

90 Park Avenue. 17th Floor

New York, NY 10016

212.430.0360

[email protected]

 

SOURCE: Viveve Medical, Inc.

 

Released May 21, 2015